Q-Line Biotech Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 1.58 Cr
as on 13-12-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 192.32 Cr
as on 13-12-2024
- Satisfied Charges ₹ 8.72 Cr
as on 13-12-2024
- Revenue 68.34%
(FY 2022)
- Profit 238.45%
(FY 2022)
- Ebitda 203.05%
(FY 2022)
- Net Worth 100.33%
(FY 2022)
- Total Assets 95.10%
(FY 2022)
About Q-Line Biotech
The Corporate was formerly known as Sperogenx Lifesciences Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 1.58 Cr.
The company currently has active open charges totaling ₹192.32 Cr. The company has closed loans amounting to ₹8.72 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pushplata Garg, Amita Garg, Saurabh Garg, and Four other members serve as directors at the Company.
- CIN/LLPIN
U74120UP2010PTC042528
- Company No.
042528
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Q-Line Biotech Private Limited offer?
Q-Line Biotech Private Limited offers a wide range of products and services, including Pathology Lab Equipments, Elisa Reader, IVDs & Analyzers, Urine Analyzer, Rapid Test Kit, Diagnostic Test Kit, Dengue Test Kit, Analyzers & Analytical Instruments, Elemental Analyzer, Industrial Chemicals & Supplies.
Who are the key members and board of directors at Q-Line Biotech?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Mahanty  | Director | 12-Jan-2015 | Current |
| Pushplata Garg | Director | 10-Nov-2010 | Current |
| Amita Garg | Director | 10-Nov-2010 | Current |
| Saurabh Garg | Director | 10-Nov-2010 | Current |
| Kuldeep Chowdhry | Director | 12-Jan-2015 | Current |
| Abhay Agrawal | Director | 12-Jan-2015 | Current |
Financial Performance of Q-Line Biotech.
Q-Line Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 68.34% increase. The company also saw a substantial improvement in profitability, with a 238.45% increase in profit. The company's net worth Soared by an impressive increase of 100.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Q-Line Biotech?
In 2022, Q-Line Biotech had a promoter holding of 95.24% and a public holding of 4.76%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Poct Science House Private LimitedActive 5 years 11 monthsAmita Garg and Saurabh Garg are mutual person
Heidelco Medicore Private LimitedActive 11 years 8 monthsAmita Garg, Saurabh Garg and 1 more are mutual person
Q-Line Healthcare Private LimitedActive 36 years 4 monthsAmita Garg, Saurabh Garg and 1 more are mutual person
- Asg Buildtech Private LimitedActive 6 years 11 months
Amita Garg, Saurabh Garg and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 May 2024 | ₹2.50 M | Open |
Others Creation Date: 21 Mar 2024 | ₹6.75 Cr | Open |
Others Creation Date: 20 Mar 2024 | ₹18.00 Cr | Open |
How Many Employees Work at Q-Line Biotech?
Q-Line Biotech has a workforce of 219 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Q-Line Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Q-Line Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
